Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVRx, Inc.CVRX · Entity 6920 | VP OF GLOBAL CLINICAL RESEARCH | October 16, 2023 | October 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVRx, Inc.
Report date October 16, 2023 · Filed October 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 778 |
Reported balance
After 2023-10-16 transaction · row 1
1 source rowRow 1 · 2023-10-16 · Exercise / conversion · Acquired 778 · Balance 778 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.24 · Expires 2023-11-11 | Direct | 0 |
Reported balance
After 2023-10-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-10-16 · Exercise / conversion · Disposed 778 · Balance 0 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2023 Filed Oct 18, 2023 16:51 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionStock Option (right to buy) · Derivative | 778 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-23-014406 · form4-10182023_081024.xml · derivative · entry 2 Galle Liz · CIK 0001869353 · VP OF GLOBAL CLINICAL RESEARCH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 778 shares Expires 2023-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 16:51 UTC | CVRx, Inc. CVRX · Entity 6920 | Exercise / conversionCommon Stock | 778 | $0.24 | $184.39 |
DisclosureSEC source: 0001415889-23-014406 · form4-10182023_081024.xml · nonDerivative · entry 1 Galle Liz · CIK 0001869353 · VP OF GLOBAL CLINICAL RESEARCH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 19:14 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001415889-23-001287 · form4-01212023_120100.xml · derivative · entry 1 Galle Liz · CIK 0001869353 · VP OF GLOBAL CLINICAL RESEARCH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-01-17 F1 · derivative.exercise_date: Vests as to 25% of the shares on January 18, 2024 and as to 1/48th of the shares each month thereafter. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:25 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001415889-22-008287 · form4-08042022_050857.xml · derivative · entry 1 Galle Liz · CIK 0001869353 · VP OF GLOBAL CLINICAL RESEARCH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2032-08-01 F1 · derivative.exercise_date: Vests as to 25% of the shares on August 2, 2023 and as to 1/48th of the shares each month thereafter. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 18:14 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 25,900 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001179110-22-000545 · edgar.xml · derivative · entry 1 Galle Liz · CIK 0001869353 · VP of Global Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,900 Underlying: Common Stock · 25,900 shares Expires 2032-01-17 F1 · derivative.exercise_date: Vests as to 25% of the shares on January 18, 2023 and as to 1/48th of the shares each month thereafter. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 17:28 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 19,700 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001179110-21-007265 · edgar.xml · derivative · entry 1 Galle Liz · CIK 0001869353 · VP of Global Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,700 Underlying: Common Stock · 19,700 shares Expires 2031-06-28 F1 · derivative.exercise_date: Vests as to 25% of the shares on June 29, 2022 and as to 1/48th of the shares each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.